Abstract
The acquired immune deficiency syndrome (AIDS) has become an important health problem around the world. It is estimated at this writing that more than one million Americans have been exposed to the HTLV III/LAV, the etiologic agent of AIDS. Because HTLV III/LAV causes progressive and severe immune deficiency resulting in death due to opportunistic infections and certain malignancies (especially Kaposi's sarcoma and lymphomas), the treatment for those already exposed to HTLV III/LAV includes approaches that would result in destruction and/or containment of HTLV III/LAV and the reconstitution and/or immune enhancement of the host. In this brief review. Sudhir Gupta will present the ‘state of the art' of the genomic structure of the HTLV III/LAV and the treatments against HTLV III/LAV (anti-viral) and those resulting in immunoreconstitution/immunopotentiation of the host.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
